AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00734682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal CPT-11
Description: Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m\^2 (wild type) or 60 mg/m\^2 IV q3 weeks.
Study NCT03064906 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Insulet AP (artificial pancreas) System
Description: Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
Study NCT02170207 — intervention group
Intervention type: DRUG
Intervention: Lansoprazole
Description: Lansoprazole 30 mg injection
Study NCT04263688 — intervention group
Intervention type: OTHER
Intervention: Non-Intervention
Description: Non-Intervention
Study NCT00447122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000mg/m2 100minutes
Description: 1000mg/m2 100minutes
Study NCT02627794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restora™ Steroid eluting spacer
Description: The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
Study NCT00447122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 100mg/m2
Description: 100mg/m2
Study NCT02627794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silastic Silicone Spacer
Description: The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
Study NCT05647538 — intervention group
Intervention type: PROCEDURE
Intervention: Bilateral uterine artery ligation
Description: Bilateral UAL was done 2 cm under the Kerr incision (lower segment transverse). A 2-Vicryl absorbable suture (Ethicon, Neuilly-surSeine, France) was introduced from the anterior to posterior views of the myometrium 2-3 cm medial to the descending part of the uterine vessels within an avascular area in the broad ligament and tied. Following the surgery, the uterine tone and hemorrhage were managed.
Study NCT00915551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (Ingenol Mebutate) gel, 0.015%
Description: once daily for 3 consecutive days
Study NCT00915551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: once daily for 3 consecutive days
Study NCT02039856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multilevel stakeholder engagement
Description: Structured, in-person stakeholder panel meeting of VA network, VA medical center, and primary care and women's health leaders using modified Delphi panel techniques to come to consensus on a quality improvement (QI) roadmap within each participating VA network, followed by intermittent progress reporting and post-24 months in-person capstone stakeholder panel meetings
Study NCT02039856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality improvement (QI) education/training
Description: Initial in-person and ongoing virtual team training in QI principles, methods, and project proposal development and refinement
Study NCT03137849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Poses
Description: Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
Study NCT02540460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 1200mg BID
Description: LCB01-0371 1200mg BID
Study NCT02540460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02540460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02109614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release Niacin
Description: Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
Study NCT02109614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Comparator arm will be taking 1500mg of the placebo daily
Study NCT03854656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~1. The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~2. The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
Study NCT03836547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching and Weight Loss for patients with dyspnea
Description: Patients with lung disease and a BMI of 35 or greater who suffer from shortness of breath will be invited to participate in a study involving a commercial weight loss application with health coaching. The patients will subscribe on their own to the weight loss application. The patients will be provided with a blue tooth scale so that they may weigh themselves weekly. A health coach will call them weekly for 8 weeks.
Study NCT03836547 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will receive usual care for 12 weeks followed by the active intervention.
Study NCT03025542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
Study NCT03025542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive injections of Placebo.
Study NCT02039856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technical support
Description: Research team provided technical review of and feedback on local QI project proposals, helped develop and/or recommend process/outcome measures, identified and shared relevant published literature (e.g., measures, interventions), and provided general technical support (e.g., how to analyze local data, how to conduct a local focus group)
Study NCT02039856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formative feedback
Description: Research team provided aggregated all-site and local data from baseline patient and provider/staff surveys, 12-month patient surveys, and other data and findings to local teams for ongoing and new QI project idea development
Study NCT02039856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External practice facilitation
Description: Within and across site calls with local teams to review progress, identify needs, help solve problems, discuss current and new projects, as well as potential for spread
Study NCT02039856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: National policy guidance
Description: VA Handbooks on policy and practice for PACT implementation guidance and on delivery of comprehensive women's health services disseminated to all VA facilities
Study NCT01384396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-3357
Description: Intravenous infusion once a day
Study NCT00616460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT \< 250
Study NCT03609515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-controlled admission
Description: The patients with a contract for patient-controlled admissions may refer themselves to short inpatient stays when they feel the need, without needing an approval from a clinician. They will be accepted for admission if a patient-controlled bed is available in the ward. Patient-controlled admissions are limited to a length of 5 days and at least three weeks between such stays.
Study NCT03281954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose.
Study NCT03281954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose.
Study NCT02310685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive e-health wellness program
Description: Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not of interest.
Study NCT04295421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
Study NCT04295421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adductor canal block
Description: ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
Study NCT04295421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPACK block
Description: IPACK block was realized after spinal anesthesia with 40 ml 0.2% ropivacaine and at the end of surgery , patients were given ACB with 20 ml 0.2% ropivacaine and continued with 4 ml/H saline for 48H
Study NCT01299623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors
Description: Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
Study NCT01459965 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with 10 French biliary plastic stent placement
Description: Stent placement of a 10 French biliary plastic stent
Study NCT01459965 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with 11.5 French biliary plastic stent
Description: biliary plastic stent placement
Study NCT01154309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for Depression and AOD Disorders
Description: 18 sessions of 2-hour group CBT
Study NCT03951740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Charge 2
Description: Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
Study NCT03951740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mio Slice
Description: Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
Study NCT03951740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxycon Mobile
Description: The Oxycon Mobile will be used as the reference method/golden standard to calculate energy expenditure (kcal). This device (consisting of a face mask and gas analyzer unit) will be worn during the entire laboratory activity protocol.~Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
Study NCT00380978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined spinal epidural analgesia
Description: Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
Study NCT00380978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: late analgesia (systemic)
Description: Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
Study NCT03147365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).
Study NCT03147365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified strength training
Description: Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
Study NCT00786487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% lipid infusion
Description: 1.5 ml/min for 6 hours
Study NCT03137849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breath Control
Description: Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration.
Study NCT03137849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
Study NCT02535585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: knotted anchors (SutureTak biocomposite 3.0 mm)
Description: Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
Study NCT02535585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: knotless anchors (PushLock biocomposite 2.9 mm knotless)
Description: Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
Study NCT01051648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra ocular injection of triamcinolone acetonide
Description: In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly \& completely as possible after finishing anterior vitrectomy
Study NCT03610984 — intervention group
Intervention type: OTHER
Intervention: type 1 diabetes structured education
Description: The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
Study NCT03610685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Given daily for 2 weeks
Study NCT03610685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Given daily for 2 weeks
Study NCT04131855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pumice prophylaxis
Description: Pumicing the teeth is the recommended prophylaxis to be used prior to the application of the self etch primer by the manufacturer - 3M Unitek Transbond Plus Self Etch Primer which will be used in the experiment.
Study NCT04131855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No pumice prophylaxis
Description: Pumice prophylaxis will not be used as per manufacturers instructions.
Study NCT03340922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic annotation of LAT (WF-method)
Description: Automatic annotation of LAT during PVC activation mapping. Acquisition of points will be automatically performed using the Wavefront (WF) annotation tool integrated into CARTO navigation system.
Study NCT02039856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: National policy guidance
Description: VA Handbooks on policy and practice for PACT implementation guidance and on delivery of comprehensive women's health services disseminated to all VA facilities
Study NCT04374058 — intervention group
Intervention type: OTHER
Intervention: less-frequency hemodialysis
Description: Patients of treatment group would be evaluated quarterly
Study NCT03340922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual annotation of LAT (M-method)
Description: Conventional, manual annotation of LAT during PVC activation mapping. Acquisition of points will be performed using the CARTO navigation system by an expert electrophysiologist.
Study NCT02296307 — intervention group
Intervention type: OTHER
Intervention: Blood test: CA-125 biomarker
Description: * CA-125 biomarker blood test at visit 1, day 1.~* CA-125 biomarker blood test at visit 2, week 6.
Study NCT02607228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily.
Study NCT02607228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Capsules administered orally once daily.
Study NCT02348307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981, (Oral single dosing)
Description: Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
Study NCT02348307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, (Oral single dosing)
Description: Subjects randomized to the placebo arm receive placebo.
Study NCT02980627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy with Mobile App Enhancement
Description: Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies.
Study NCT00586976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.3% ropivacaine infusion at 4 ml/hr for 64 hours.